

MISSION: *Science Translational Medicine* seeks to promote human health by facilitating communication and cooperation among those dedicated to basic, translational, and clinical research and its application. Published papers should present new data or ideas that significantly advance the application of basic research results to clinical medicine or otherwise contribute to the improvement of human health.

### CRITERIA FOR JUDGMENT

**Commentaries** present an overview or an analysis of a current issue of interest to the translational medicine community. They can discuss regulatory, policy, legislative, funding, or economic topics as long as they pertain to an aspect of science or medicine that affects the transformation of basic science results into improvements in clinical medicine. Opinion is welcome, but other views should be acknowledged.

**Overall Recommendation:** On the basis of the mission statement above, recommend in your review whether the Commentary should be published in *Science Translational Medicine* and provide a critique based on the following:

- 1. Importance.** Evaluate to what extent the synthesis, argument, or analysis is broadly important to the progress of translational medicine and whether it provides needed insight to the community.
- 2. Novelty.** Assess whether the Commentary provides an original idea or synthesis. If it is not completely original, will the community benefit by its presentation in a widely available, accessible format? Are previous authors properly credited?
- 3. Clarity of Presentation.** The arguments should flow logically and be supported by references or data.
- 4. References and Length.** Commentaries should be between 1000 and 3000 words long plus one or two figures. The reference list should emphasize the most recent literature and information. There should be no more than 15 references.

**Conflict of Interest:** If you cannot judge this paper impartially, please notify us immediately. If you have any financial or professional affiliations that may be perceived as a conflict of interest in reviewing the manuscript, describe these as indicated on our online review form.

**Confidentiality:** We expect reviewers to protect the confidentiality of the manuscript and ensure that it is not disseminated or exploited. Please destroy your copy of the manuscript when you are done. Only discuss the paper with a colleague with permission from the editor. We do not disclose the identity of our reviewers.

**Security:** Please inform us if you have concerns that release of this Commentary may pose a danger to public health, safety, or security. Such concerns will be brought to the attention of the Chief Scientific Advisor for further evaluation.

**Returning your review:** Please return your review through our *Science* Journals Manuscript Submission and Information Portal at <https://cts.sciencemag.org>. Log into your *Science* Journals account to access the paper and the review form. If necessary, we can also receive reviews by e-mail at [scitranslmed-review@aaas.org](mailto:scitranslmed-review@aaas.org).

*Final selection is based on relative quality of papers rather than absolute merit and is constrained by available space in Science Translational Medicine and our commitment to balance subject matter.*